ALDX Q4 2025 Earnings — Aldeyra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALDXAldeyra Therapeutics, Inc.

$318M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$65,115

Operating Income

-$7M

Net Income

-$6M

EPS (Diluted)

$-0.11

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

$28.2T

Free Cash Flow

$28.2T

Stock-Based Comp.

-$3.6T

Balance Sheet

Total Assets

$72.1T

Total Liabilities

$27.8T

Stockholders' Equity

$44.3T

Cash & Equivalents

$70.0T

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$65,115	-$64,373	-1.2%
Operating Income	-$7M	-$17M	+59.8%
Net Income	-$6M	-$16M	+59.1%